Gilead Sciences: Long-acting HIV-1 shell inhibitor Lenacapavir (GS-6207) clinically performs well

Gilead Sciences today released the latest data from an ongoing Phase 1 clinical study showing that the experimental HIV-1 shell function inhibitor Lenacapavir (GS-6207) is expected to last at least six months after a single 900 mg doseIn this study, Lenacapavir had good tolerance and no serious adverse reactions were reportedThese figures will be presented at the 23rd International AIDS ConferenceDrEric SDaar, a professor of medicine at the David Geffen School of Medicine at UCLA, said: "Long-acting antiretroviral therapy can help address patient compliance and provide more treatment options for people living with HIVLenacapavir's safety and pharmacokinetic characteristics support a long-acting regimen that is administered every 6 months."Lenacapavir is a research drug that is being used in combination with other antiretroviral drugs as part of a long-acting treatment programmeLenacapavir destroys the HIV shell at several stages of the virus's life cycle, which is a multi-polymer that is necessary for virus replicationIn May 2019, theFDAawarded Lenacapavir breakthrough therapy for treatment of multidrug-resistant AIDS patients